DBV Technologies S.A. (DBVT)Healthcare | Biotechnology | Châtillon, France | NasdaqCM
21.34 USD
+0.73
(3.542%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 21.34 Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:33 p.m. EDT
DBVT offers a high-conviction short-term bullish setup driven by recent momentum, analyst upgrades following pivotal clinical trial data, and a strong risk/reward skewed to upside, despite a binary long-term profile with negative earnings and no dividend yield. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.055582 |
| AutoETS | 0.055585 |
| MSTL | 0.075205 |
| AutoTheta | 0.110922 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.386 |
| Excess Kurtosis | -0.97 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.867 |
| Revenue per Share | 0.2 |
| Market Cap | 1,262,962,560 |
| Forward P/E | -80.22 |
| Beta | -0.20 |
| Website | https://www.dbv-technologies.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3950617 |
| Address1 | Bâtiment IRO |
| Address2 | 107 Av. de la REpublique |
| All Time High | 101.14 |
| All Time Low | 0.441 |
| Ask | 21.37 |
| Ask Size | 1 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 198,250 |
| Average Daily Volume3 Month | 312,230 |
| Average Volume | 312,230 |
| Average Volume10Days | 198,250 |
| Beta | -0.196 |
| Bid | 21.0 |
| Bid Size | 1 |
| Book Value | 3.58 |
| City | Châtillon |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.34 |
| Current Ratio | 3.67 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 21.59 |
| Day Low | 20.8873 |
| Debt To Equity | 3.867 |
| Display Name | DBV |
| Earnings Call Timestamp End | 1,722,375,000 |
| Earnings Call Timestamp Start | 1,722,375,000 |
| Earnings Timestamp | 1,777,579,200 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | -143,862,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -33.643 |
| Enterprise To Revenue | 858.762 |
| Enterprise Value | 4,839,981,568 |
| Eps Current Year | -0.4512 |
| Eps Forward | -0.2660246 |
| Eps Trailing Twelve Months | -5.25 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.1451 |
| Fifty Day Average Change | 0.19490051 |
| Fifty Day Average Change Percent | 0.00921729 |
| Fifty Two Week Change Percent | 139.50618 |
| Fifty Two Week High | 26.185 |
| Fifty Two Week High Change | -4.8449993 |
| Fifty Two Week High Change Percent | -0.18502958 |
| Fifty Two Week Low | 7.526 |
| Fifty Two Week Low Change | 13.814 |
| Fifty Two Week Low Change Percent | 1.8355036 |
| Fifty Two Week Range | 7.526 - 26.185 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,413,984,600,000 |
| Float Shares | 165,986,935 |
| Forward Eps | -0.2660246 |
| Forward P E | -80.21815 |
| Free Cashflow | -64,285,000 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 5,636,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.058179997 |
| Implied Shares Outstanding | 59,182,876 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,717,718,400 |
| Last Split Factor | 1:2 |
| Long Business Summary | DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France. |
| Long Name | DBV Technologies S.A. |
| Market | us_market |
| Market Cap | 1,262,962,560 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_7406282 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -146,947,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,263,280,436 |
| Number Of Analyst Opinions | 6 |
| Open | 21.3 |
| Operating Cashflow | -121,181,000 |
| Operating Margins | -69.84651 |
| Payout Ratio | 0.0 |
| Phone | 33 1 55 42 78 78 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 21.34 |
| Post Market Time | 1,776,456,026 |
| Previous Close | 20.61 |
| Price Eps Current Year | -47.2961 |
| Price Hint | 2 |
| Price To Book | 5.960894 |
| Price To Sales Trailing12 Months | 224.08846 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.625 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.83333 |
| Region | US |
| Regular Market Change | 0.73 |
| Regular Market Change Percent | 3.54197 |
| Regular Market Day High | 21.59 |
| Regular Market Day Low | 20.8873 |
| Regular Market Day Range | 20.8873 - 21.59 |
| Regular Market Open | 21.3 |
| Regular Market Previous Close | 20.61 |
| Regular Market Price | 21.34 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 235,554 |
| Return On Assets | -0.61401004 |
| Return On Equity | -1.49826 |
| Revenue Growth | 0.262 |
| Revenue Per Share | 0.2 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 59,182,876 |
| Shares Percent Shares Out | 0.028499998 |
| Shares Short | 1,688,295 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,325,338 |
| Short Name | DBV Technologies S.A. |
| Short Percent Of Float | 0.0323 |
| Short Ratio | 5.93 |
| Source Interval | 15 |
| Symbol | DBVT |
| Target High Price | 52.09226 |
| Target Low Price | 5.847258 |
| Target Mean Price | 40.4552 |
| Target Median Price | 47.477055 |
| Total Cash | 194,167,008 |
| Total Cash Per Share | 0.824 |
| Total Debt | 6,526,000 |
| Total Revenue | 5,636,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.69672 |
| Two Hundred Day Average Change | 5.64328 |
| Two Hundred Day Average Change Percent | 0.3595197 |
| Type Disp | Equity |
| Volume | 235,554 |
| Website | https://www.dbv-technologies.com |
| Zip | 92,320 |